311 related articles for article (PubMed ID: 29898734)
1. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway.
Yeh YH; Hsiao HF; Yeh YC; Chen TW; Li TK
J Exp Clin Cancer Res; 2018 Mar; 37(1):70. PubMed ID: 29587825
[TBL] [Abstract][Full Text] [Related]
3. 14-3-3ζ up-regulates hypoxia-inducible factor-1α in hepatocellular carcinoma via activation of PI3K/Akt/NF-кB signal transduction pathway.
Tang Y; Lv P; Sun Z; Han L; Luo B; Zhou W
Int J Clin Exp Pathol; 2015; 8(12):15845-53. PubMed ID: 26884855
[TBL] [Abstract][Full Text] [Related]
4. Triptolide restrains the growth, invasion, stemness, and glycolysis of non-small cell lung cancer cells by PFKFB2-mediated PI3K/AKT pathway.
Ren J; Zhao S; Lai J
Chem Biol Drug Des; 2024 Jan; 103(1):e14450. PubMed ID: 38230789
[TBL] [Abstract][Full Text] [Related]
5. Investigation on the mechanism of the combination of eremias multiocellata and cisplatin in reducing chemoresistance of gastric cancer based on
Cheng FE; Li Z; Bai X; Jing Y; Zhang J; Shi X; Li T; Li W
Aging (Albany NY); 2024 Feb; 16(4):3386-3403. PubMed ID: 38345573
[TBL] [Abstract][Full Text] [Related]
6. CoCl
Fan Z; Liu Y; Lan Y; Wu Y; Li J; Xu X
Cell Biol Int; 2024 Jun; 48(6):808-820. PubMed ID: 38433534
[TBL] [Abstract][Full Text] [Related]
7. NRSN2 promotes non-small cell lung cancer cell growth through PI3K/Akt/mTOR pathway.
Zhang XY; Kuang JL; Yan CS; Tu XY; Zhao JH; Cheng XS; Ye XQ
Int J Clin Exp Pathol; 2015; 8(3):2574-81. PubMed ID: 26045763
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in non-small cell lung cancer.
Liu X; Li J; Huang Q; Jin M; Huang G
Mol Med; 2024 Apr; 30(1):56. PubMed ID: 38671369
[TBL] [Abstract][Full Text] [Related]
9. Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway.
Chen L; Yu W; Tang H; Zhang S; Wang J; Ouyang Q; Guo M; Zhu X; Huang Z; Chen J
Metallomics; 2024 Jan; 16(1):. PubMed ID: 38183290
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells.
Cluff E; Magdaleno CC; Fernandez E; House T; Swaminathan S; Varadaraj A; Rajasekaran N
Cancer Immunol Immunother; 2022 Aug; 71(8):1989-2005. PubMed ID: 34999917
[TBL] [Abstract][Full Text] [Related]
12. Kinetochore scaffold 1 downregulation suppressed the development of non-small cell lung cancer by inactivating the phosphatidylinositol 3 kinase/protein kinase B (AKT)/nuclear factor-kappa B pathway.
Wu L; Zhang G; Zhu Q; Huang Y
J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583438
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma.
Zhou S; Deng M; Bian X; Shi J; Liang R; Tao M
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):120-127. PubMed ID: 38430032
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway.
Koshikawa N; Hayashi J; Nakagawara A; Takenaga K
J Biol Chem; 2009 Nov; 284(48):33185-94. PubMed ID: 19801684
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 3 suppresses proliferation and cisplatin resistance of cervical cancer cells by inactivation of the PI3K/AKT pathway.
Chen R; Fang T; Liu N; Shi X; Wang J; Yu H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2269-2280. PubMed ID: 37812238
[TBL] [Abstract][Full Text] [Related]
17. 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells.
Wang SF; Chou YC; Mazumder N; Kao FJ; Nagy LD; Guengerich FP; Huang C; Lee HC; Lai PS; Ueng YF
Biochem Pharmacol; 2013 Aug; 86(4):548-60. PubMed ID: 23792120
[TBL] [Abstract][Full Text] [Related]
18. miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway.
Duan J; Wang L; Shang L; Yang S; Wu H; Huang Y; Miao Y
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33269380
[TBL] [Abstract][Full Text] [Related]
19. Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells.
Aldonza MB; Hong JY; Bae SY; Song J; Kim WK; Oh J; Shin Y; Lee SH; Lee SK
PLoS One; 2015; 10(6):e0127841. PubMed ID: 26098947
[TBL] [Abstract][Full Text] [Related]
20. The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.
Xiaoyu H; Yiru Y; Shuisheng S; Keyan C; Zixing Y; Shanglin C; Yuan W; Dongming C; Wangliang Z; Xudong B; Jie M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818780063. PubMed ID: 29916308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
